Xoma Technology Ltd.

Novartis Ag

Biosite Diagnostics, Inc.

Biosite Incorporated

Other

Medarex Inc.

Joe Buechler

Jeff Gray

Gunars E Valkirs

Uday Kumar Veeramallu

Nils Lonberg

Emma Michelle Campbell

Sofia Parveen

Shanthi Govindaraj

The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Nucleic acid encoding anti-IL13 human antibodies

Methods of using anti-IL13 human antibodies

Method of using anti-IL-13 antibodies

The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences.

Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries

Anti-IL13 human antibodies

The invention provides in vitro methods of detection using human antibodies. The methods are particularly useful for analyzing human samples containing HAMA or heterophilic antibodies. A human antibody can bind to an analyte in such samples without binding to HAMA or heterophilic antibodies present in the samples. The methods can be effected using a sandwich format among others.

Human antibodies as detection reagents

The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expressing human immunoglobulins. Such screening produces unlimited numbers of high affinity human antibodies to any target of interest.

Human antibodies

Eukaryotic signal sequences for prokaryotic expression

This invention provides a novelprotein disulfide isomerase polypeptide, and nucleic acids that encode this polypeptide. The invention also provides methods, reagents, and kits that are useful for diagnosing infection by. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the protein disulfide isomerase polypeptide of

[object Object]

The invention is directed to inter alia two related but self-sufficient improvements in conventional display methods. The first improvement provides methods of enriching conventional display libraries for members displaying more than one copy of a polypeptide prior to affinity screening of such libraries with a target of interest. These methods can achieve diverse populations in which the vast majority of members retaining full-length coding sequences encode polypeptides having specific affinity for the target. In a second aspect, the invention provides methods of subcloning nucleic acids encoding displayed polypeptides of enriched libraries from a display vector to an expression vector without the need for clonal isolation of individual members. These methods result in polyclonal libraries of antibodies and other polypeptides for use, e.g., as diagnostic or therapeutic reagents.

Polyvalent display libraries

This invention provides methods, reagents, and kits that are useful for diagnosing infection by. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, that bind to the &#x3b1;-1-giardin antigen of

Diagnostic assays for detection of Giardia lamblia

The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expresing human immunoglobulins. Such screening produces unlimited numbers of high affinity human antibodies to any target of interest.

Growing community of inventors

Carlsbad, CA, United States of America

Joe Buechler